Prothena Corporation plc (PRTA)

Market Cap	1.14B
Revenue (ttm)	91.37M
Net Income (ttm)	-147.03M
Shares Out	53.72M
EPS (ttm)	-2.76
PE Ratio	n/a
Forward PE	64.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	495,825
Open	20.56
Previous Close	20.57
Day's Range	20.42 - 21.18
52-Week Range	20.42 - 79.65
Beta	0.24
Analysts	Buy
Price Target	67.14 (+217.3%)
Earnings Date	May 2, 2024

About PRTA

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 173
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTA

Financial Performance

In 2023, PRTA's revenue was $91.37 million, an increase of 69.50% compared to the previous year's $53.91 million. Losses were -$147.03 million, 25.7% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $67.14, which is an increase of 217.30% from the latest price.

Price Target

$67.14

(217.30% upside)

Analyst Consensus: Buy